Literature DB >> 11347971

A1 adenosine receptors and their ligands: overview and recent developments.

C E Müller1.   

Abstract

Potent adenosine receptor (AR) agonists and antagonists with high selectivity for the A1AR subtype have been developed during the past decades. However, some of the compounds considered to be selective may not be as selective in humans as in rats, and may not be very selective versus the new AR subtypes A3 or A2B. Partial agonists have been developed that may exhibit fewer side effects than full agonists. Low water solubility of many A1 antagonists remains a problem. A1 AR antagonists can be classified as neutral antagonists or inverse agonists; the pharmacological consequences of inverse agonism versus neutral antagonism will have to be the subject of future investigations. Some medicinal plants (e.g. Hypericum perforatum and Valeriana officinalis) contain compounds that are antagonists or partial agonists at A1 ARs; effects on ARs may contribute to their pharmacological activity. 18F- and 11C-labeled A1 AR antagonists have been developed for positron emission tomography studies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11347971     DOI: 10.1016/s0014-827x(01)01005-9

Source DB:  PubMed          Journal:  Farmaco        ISSN: 0014-827X


  4 in total

1.  Molecular mechanism of allosteric modulation at GPCRs: insight from a binding kinetics study at the human A1 adenosine receptor.

Authors:  Dong Guo; Suzanne N Venhorst; Arnault Massink; Jacobus P D van Veldhoven; Georges Vauquelin; Adriaan P IJzerman; Laura H Heitman
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

2.  Allosteric modulation, thermodynamics and binding to wild-type and mutant (T277A) adenosine A1 receptors of LUF5831, a novel nonadenosine-like agonist.

Authors:  Laura H Heitman; Thea Mulder-Krieger; Ronald F Spanjersberg; Jacobien K von Frijtag Drabbe Künzel; Alessandro Dalpiaz; Adriaan P IJzerman
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

3.  Design, synthesis and evaluation of amino-3,5-dicyanopyridines and thieno[2,3-b]pyridines as ligands of adenosine A1 receptors for the potential treatment of epilepsy.

Authors:  Gaofenngwe Nkomba; Gisella Terre'Blanche; Helena D Janse van Rensburg; Lesetja J Legoabe
Journal:  Med Chem Res       Date:  2022-05-24       Impact factor: 2.351

4.  C3 amino-substituted chalcone derivative with selective adenosine rA1 receptor affinity in the micromolar range.

Authors:  Helena D Janse van Rensburg; Lesetja J Legoabe; Gisella Terre'Blanche
Journal:  Chem Zvesti       Date:  2020-11-17       Impact factor: 2.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.